Modern 
Mrna After postponing the offering of some Gowight vaccines in the UK next year, it reduced its forecast for revenue to 2025 on Friday, which hid that it had a lower loss than in the second quarter and their actions led to a decline.
The new forecast reflects a series of challenges faced by the vaccine manufacturer, between $ 1.5 billion and $ 2.2 billion, which deals with the need for the AA Gov -19, which is slowly out of the respiratory syndrome (RSV) and regulatory delays in its new product pipe.
The company is under pressure to reduce costs and resume growth after the profits made during infections are over.
Modern claimed that this year's revenue would be recognized in revenue this year, and the rest are expected in the fourth quarter.
“The change in the table is caused by the use of minimum product procurement allocation for spring campaign in the fiscal year 2026,” said Chief Finance Officer James Moke, which this would not affect the total value of the modern Bloryal agreement with the United Kingdom.
According to LSEG Data, quarterly revenue is 2 142 million and 41% dropped over the previous year, but $ 112.9 million has been announced ahead of the estimates of $ 112.9 million.
At the adjusted site, modernity recorded a quarter loss per share, while researchers lost an average of $ 2.97 per share.
The new MRNA products are made of Moderna betting, ie an integrated test vaccination and fever to resume growth against Gov -19.
The company said it was not expecting a significant impact on production costs due to recent fees.
Modern claimed that the cost of operating costs is $ 400 million by 2025, which is between $ 5.9 billion and $ 6.1 billion.
(Patrick Wingrov in New York and Puayan Singh and Sneha SK in Bangalore.
((Sawo Paulo Newsroom Translation))
